HRP20180301T1 - Postupci liječenja psorijaze uporabom il-17 antagonista - Google Patents
Postupci liječenja psorijaze uporabom il-17 antagonista Download PDFInfo
- Publication number
- HRP20180301T1 HRP20180301T1 HRP20180301TT HRP20180301T HRP20180301T1 HR P20180301 T1 HRP20180301 T1 HR P20180301T1 HR P20180301T T HRP20180301T T HR P20180301TT HR P20180301 T HRP20180301 T HR P20180301T HR P20180301 T1 HRP20180301 T1 HR P20180301T1
- Authority
- HR
- Croatia
- Prior art keywords
- secukinumab
- patient
- psoriasis
- treatment
- use according
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title claims 7
- 239000005557 antagonist Substances 0.000 title 1
- 229960004540 secukinumab Drugs 0.000 claims 13
- 238000012423 maintenance Methods 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- 238000009121 systemic therapy Methods 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Secukinumab, naznačen time, da se upotrebljava u liječenju psorijaze, pri čemu se pacijentu kojemu je to potrebno, treba davati pet tjednih doza od 150 mg do 300 mg secukinumaba; te time, da nakon toga pacijentu treba davati od 150 mg do 300 mg secukinumaba mjesečno.
2. Secukinumab za uporabu prema zahtjevu 1, naznačen time, da svaka doza iznosi 150 mg.
3. Secukinumab za uporabu prema zahtjevu 1, naznačen time, da svaka doza iznosi 300 mg.
4. Secukinumab za uporabu u liječenju psorijaze, naznačen time, da se treba davati 300 mg secukinumaba pacijentu kojemu je to potrebno, pomoću subkutane injekcije, s početnom dozom nakon nultog, prvog, drugog i trećeg tjedna, te nakon toga slijedi mjesečno održavanje doziranja počevši nakon četvrtog tjedna.
5. Secukinumab za uporabu u liječenju psorijaze, naznačen time, da se treba davati 150 mg secukinumaba pacijentu kojemu je to potrebno, pomoću subkutane injekcije, s početnom dozom nakon nultog, prvog, drugog i trećeg tjedna, te zatim slijedi mjesečno održavanje doziranja počevši nakon četvrtog tjedna.
6. Secukinumab za uporabu prema zahtjevu 1 do 5, naznačen time, da se kod psorijaze radi o umjereno jakoj do ozbiljno jakoj psorijazi vulgaris.
7. Secukinumab za uporabu prema zahtjevu 1 do 6, naznačen time, da se kod pacijenta radi o odraslom pacijentu koji je kandidat za sustavnu terapiju.
8. Secukinumab za uporabu u liječenju umjereno jake do ozbiljno jake psorijaze vulgaris kod odraslog pacijenta koji je kandidat za sustavnu terapiju, naznačen time, da se treba davati 150 mg ili 300 mg secukinumaba pacijentu putem subkutane injekcije, s početnom dozom nakon nultog, prvog, drugog, trećeg i četvrtog tjedna, dok nakon toga slijedi mjesečno održavanje doziranja.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39138810P | 2010-10-08 | 2010-10-08 | |
| PCT/EP2011/067522 WO2012045848A1 (en) | 2010-10-08 | 2011-10-07 | Methods of treating psoriasis using il-17 antagonists |
| EP11764764.4A EP2625199B1 (en) | 2010-10-08 | 2011-10-07 | Methods of treating psoriasis using il-17 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180301T1 true HRP20180301T1 (hr) | 2018-03-23 |
Family
ID=44759699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180301TT HRP20180301T1 (hr) | 2010-10-08 | 2018-02-20 | Postupci liječenja psorijaze uporabom il-17 antagonista |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9717791B2 (hr) |
| EP (4) | EP3792281A1 (hr) |
| JP (2) | JP5537740B2 (hr) |
| KR (3) | KR20150018595A (hr) |
| CN (2) | CN107029234A (hr) |
| AU (1) | AU2011311482B2 (hr) |
| BR (1) | BR112013008501A2 (hr) |
| CA (1) | CA2813900C (hr) |
| CL (1) | CL2013000930A1 (hr) |
| CY (1) | CY1119942T1 (hr) |
| DK (1) | DK2625199T3 (hr) |
| ES (1) | ES2660770T3 (hr) |
| HK (1) | HK1247932A1 (hr) |
| HR (1) | HRP20180301T1 (hr) |
| HU (1) | HUE038334T2 (hr) |
| IL (1) | IL225310A (hr) |
| LT (1) | LT2625199T (hr) |
| MA (1) | MA34646B1 (hr) |
| MX (1) | MX356279B (hr) |
| NO (1) | NO2625199T3 (hr) |
| PL (1) | PL2625199T3 (hr) |
| PT (1) | PT2625199T (hr) |
| RU (2) | RU2665954C1 (hr) |
| SG (1) | SG188979A1 (hr) |
| SI (1) | SI2625199T1 (hr) |
| TW (2) | TWI564022B (hr) |
| WO (1) | WO2012045848A1 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2011088120A1 (en) | 2010-01-15 | 2011-07-21 | Amgen Inc. | Antibody formulation and therapeutic regimens |
| BR112012029588A2 (pt) | 2010-05-20 | 2017-07-25 | Ablynx Nv | materiais biológicas relacionados a her3. |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| KR20140097178A (ko) * | 2011-11-21 | 2014-08-06 | 노파르티스 아게 | IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법 |
| JP2016517408A (ja) * | 2013-03-15 | 2016-06-16 | アムジェン インコーポレイテッド | 抗ｉｌ−２３抗体を用いた乾癬の治療方法 |
| AU2014228553B2 (en) * | 2013-03-15 | 2019-01-24 | Amgen Inc. | Methods for treating Crohn's disease using an anti-IL23 antibody |
| US10434172B2 (en) * | 2013-08-15 | 2019-10-08 | Novartis Ag | Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists |
| WO2015099167A1 (ja) * | 2013-12-27 | 2015-07-02 | 国立大学法人大阪大学 | Ｉｌ－１７ａを標的とするワクチン |
| RU2577228C2 (ru) * | 2014-03-14 | 2016-03-10 | Закрытое Акционерное Общество "Биокад" | Анти-il-17-антитела, способ их получения и способ применения |
| US20170174772A1 (en) * | 2014-03-31 | 2017-06-22 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10039810B2 (en) | 2014-05-15 | 2018-08-07 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies |
| AU2015307868B2 (en) * | 2014-08-26 | 2020-08-27 | Amgen K-A, Inc. | Method for treating psoriasis patient which received anti-TNF-alpha antibody therapy |
| WO2016038538A1 (en) * | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA2978449A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| WO2017072183A1 (en) * | 2015-10-27 | 2017-05-04 | Ucb Biopharma Sprl | Methods of treatment using anti-il-17a/f antibodies |
| JP2019521156A (ja) * | 2016-07-19 | 2019-07-25 | ノバルティス アーゲー | Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法 |
| JP2019505516A (ja) * | 2016-11-28 | 2019-02-28 | ノバルティス アーゲー | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 |
| WO2018158741A1 (en) * | 2017-03-03 | 2018-09-07 | Novartis Ag | Psoriasis disease modification following long-term treatment with an il-17 antagonist |
| EP3672988A1 (en) * | 2017-08-23 | 2020-07-01 | Eli Lilly and Company | Treatment of genital psoriasis |
| TWI725532B (zh) * | 2018-09-11 | 2021-04-21 | 美商美國禮來大藥廠 | 治療牛皮癬之方法 |
| US20220267432A1 (en) | 2019-07-30 | 2022-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Method for treating autoimmune disease by il-17 antagonist |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| WO2023186174A1 (en) * | 2022-04-01 | 2023-10-05 | Zai Lab (Shanghai) Co., Ltd. | Topical formulation comprising an il-17a binding molecule and uses thereof |
| CN116593718B (zh) * | 2023-07-18 | 2023-09-15 | 军科正源（北京）药物研究有限责任公司 | 用于检测司库奇尤单抗抗药性抗体的试剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9422306D0 (en) * | 1994-11-04 | 1994-12-21 | Sandoz Ltd | Organic compounds |
| US6093745A (en) * | 1997-11-25 | 2000-07-25 | Psorx, L.L.C. | Methods and composition for treating skin proliferative diseases |
| AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| EP1933869B1 (en) * | 2005-09-01 | 2009-10-14 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| EP3366702B1 (en) * | 2005-12-13 | 2023-08-09 | Eli Lilly And Company | Anti-il-17 antibodies |
| TW200815469A (en) * | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| RU2367429C2 (ru) | 2007-01-30 | 2009-09-20 | Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН | Способ лечения псориаза |
| WO2008150490A2 (en) * | 2007-06-01 | 2008-12-11 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriasis and crohn's disease |
| RU2341272C1 (ru) * | 2007-10-22 | 2008-12-20 | Левон Никитович Мкртчян | Средство для неспецифической иммунотерапии |
| CN102617735B (zh) * | 2008-09-29 | 2015-09-09 | 罗氏格黎卡特股份公司 | 针对人il17的抗体及其应用 |
-
2011
- 2011-10-07 CN CN201710261381.2A patent/CN107029234A/zh active Pending
- 2011-10-07 AU AU2011311482A patent/AU2011311482B2/en active Active
- 2011-10-07 JP JP2013532213A patent/JP5537740B2/ja active Active
- 2011-10-07 NO NO11764764A patent/NO2625199T3/no unknown
- 2011-10-07 CA CA2813900A patent/CA2813900C/en active Active
- 2011-10-07 CN CN2011800487322A patent/CN103154031A/zh active Pending
- 2011-10-07 ES ES11764764.4T patent/ES2660770T3/es active Active
- 2011-10-07 SG SG2013018486A patent/SG188979A1/en unknown
- 2011-10-07 EP EP20187002.9A patent/EP3792281A1/en active Pending
- 2011-10-07 US US13/876,367 patent/US9717791B2/en active Active
- 2011-10-07 PL PL11764764T patent/PL2625199T3/pl unknown
- 2011-10-07 KR KR1020147036815A patent/KR20150018595A/ko not_active Application Discontinuation
- 2011-10-07 LT LTEP11764764.4T patent/LT2625199T/lt unknown
- 2011-10-07 EP EP17195148.6A patent/EP3299390A1/en active Pending
- 2011-10-07 SI SI201131408T patent/SI2625199T1/en unknown
- 2011-10-07 TW TW105116323A patent/TWI564022B/zh active
- 2011-10-07 DK DK11764764.4T patent/DK2625199T3/en active
- 2011-10-07 RU RU2016120615A patent/RU2665954C1/ru active
- 2011-10-07 EP EP11764764.4A patent/EP2625199B1/en active Active
- 2011-10-07 BR BR112013008501A patent/BR112013008501A2/pt active Search and Examination
- 2011-10-07 MX MX2013003916A patent/MX356279B/es active IP Right Grant
- 2011-10-07 TW TW100136608A patent/TWI548419B/zh active
- 2011-10-07 PT PT117647644T patent/PT2625199T/pt unknown
- 2011-10-07 WO PCT/EP2011/067522 patent/WO2012045848A1/en active Application Filing
- 2011-10-07 RU RU2013120957/15A patent/RU2591083C2/ru active
- 2011-10-07 EP EP22186296.4A patent/EP4137514A1/en active Pending
- 2011-10-07 HU HUE11764764A patent/HUE038334T2/hu unknown
- 2011-10-07 KR KR1020137011792A patent/KR20130110179A/ko not_active Application Discontinuation
- 2011-10-07 KR KR1020147018691A patent/KR101620771B1/ko active IP Right Grant
-
2013
- 2013-03-18 IL IL225310A patent/IL225310A/en active IP Right Grant
- 2013-04-05 CL CL2013000930A patent/CL2013000930A1/es unknown
- 2013-05-03 MA MA35872A patent/MA34646B1/fr unknown
- 2013-12-09 JP JP2013253745A patent/JP2014114288A/ja not_active Withdrawn
-
2017
- 2017-06-22 US US15/630,577 patent/US10583190B2/en active Active
-
2018
- 2018-02-20 HR HRP20180301TT patent/HRP20180301T1/hr unknown
- 2018-02-22 CY CY20181100220T patent/CY1119942T1/el unknown
- 2018-06-01 HK HK18107225.2A patent/HK1247932A1/zh unknown
-
2019
- 2019-12-19 US US16/720,351 patent/US11534490B2/en active Active
-
2020
- 2020-12-18 US US17/127,738 patent/US20210113688A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,724 patent/US20210162044A1/en not_active Abandoned
-
2022
- 2022-12-02 US US18/061,227 patent/US20230321231A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180301T1 (hr) | Postupci liječenja psorijaze uporabom il-17 antagonista | |
| HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
| JP2014111603A5 (hr) | ||
| NO20092323L (no) | Doserings- og drivmekanisme for legemiddelleveringsanordning | |
| EA201070757A1 (ru) | Режим дозирования инъекционных препаратов эфиров палиперидона длительного действия | |
| EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| JP2012180381A5 (hr) | ||
| MX2018013827A (es) | Sistema y metodo de dosificacion radiologica. | |
| CY1124734T1 (el) | Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| EA033448B1 (ru) | Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений | |
| FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
| BR112017021383A2 (pt) | regime de dosagem para doses omitidas de ésteres de paliperidona injetáveis de longa ação | |
| HRP20200019T1 (hr) | Terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| CY1120176T1 (el) | Μεθοδος για τη μειωση των συμπτωματων που μοιαζουν με αυτα της γριπης που συνδεονται με ενδομυϊκη χορηγηση ιντερφερονης με τη χρηση ενος σχηματος κλιμακουμενης δοσολογιας ταχειας τιτλοδοτησης | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| TW201642906A (en) | Fixed dose combination for pain relief without edema | |
| UA114840C2 (uk) | Протипухлинний агент, який включає гідрат гідрохлориду іринотекану | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| MX2020005438A (es) | Formas de dosificacion de sulfato de morfina disuasivas del abuso. | |
| MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
| AR102494A1 (es) | Métodos para tratar enfermedades oculares | |
| HRP20160811T1 (hr) | Upotreba odiparcila u liječenju mukopolisaharidoze | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой |